Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer reports positive trial data for heart disease drug Inspra

Pfizer reports positive trial data for heart disease drug Inspra

16th November 2010

Pfizer has published new clinical trial findings that demonstrate the benefits of its drug Inspra among sufferers of chronic heart failure with mild symptoms.

Data from the Emphasis-HF study showed that patients treated with Inspra plus standard therapy were 37 percent less likely to be affected by cardiovascular death or heart failure hospitalisation than those in a placebo control group.

This represented a statistically significant risk reduction, thereby enabling the treatment to meet its primary efficacy endpoint in the clinical trial.

Currently, Inspra is not authorised for use in this particular patient population in any individual market.

However, Dr Faiez Zannad, professor of therapeutics and cardiologist at the University Hospital of the Henri Poincare University of Nancy, said: "Patients such as those enrolled in Emphasis-HF typically have a poor prognosis and today's results should therefore provide real encouragement for doctors and patients alike."

Earlier this month, Pfizer published positive new clinical data from a phase III study of tasocitinib, a developmental therapy for treating rheumatoid arthritis.ADNFCR-8000103-ID-800237763-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.